#### India Equity Research | Consumer Goods May 17, 2021 **Result Update**

## **Colgate-Palmolive**

Refer to important disclosures at the end of this report

# Steady growth; margin beat on lower ad spends

- Colgate reported a steady performance in Q4, with sales growing 20% to Rs12.8bn at a two-year CAGR of 5.5%, which is slightly above most peers. EBITDA and APAT grew 60% and 63%, respectively, and came in 11% ahead of estimates on lower ad spends.
- The company's performance is slightly better though overall market share is yet to see any meaningful recovery. Early success of new innovations, pick-up in premiumization trends and market share gains in emerging channels (MT/Ecom) appear positive.
- Margin expansion was driven by pricing and better SKU/product mix. With an increase in input inflation, we expect pricing growth to continue but forecast flat margins in FY22-24E after strong gains in FY21.
- We remain positive on Colgate and expect management actions on innovations/GTM to improve growth and market share. Valuation at 35x FY23E EPS is reasonable and offers rerating potential. Maintain Buy with TP of Rs1,820 (40x Jun-23E EPS) vs. Rs1,800 earlier.

**Double-digit growth across categories; urban demand recovers strongly:** Sales grew 20%, with domestic volume growth estimated at ~16%. Sales CAGR over two years stood at 5.5%, marginally better than most peers. Management highlighted double-digit growth across categories, indicating a pick-up in toothbrushes, which were impacted in H1. Toothpaste growth was marginally higher at 20%+. Urban growth saw a comeback in Q4, while rural growth was stable. For FY21, sales grew 7%, with domestic growth of 8%+. Colgate has gained share in emerging channels of MT/Ecom and has witnessed encouraging response to innovations including Visible White (gained 80bps/120bps market share in MT/E-com), Vedshakti mouth spray (equivalent to 1% toothpaste SOM) and Gentle toothbrush (0.8-0.9 share in MT in three months). Recent launches include Colgate Magik (kids segment) and Slimsoft Naturals. Management continues to focus on innovations, providing specific benefits, and GTM initiatives to regain market share and drive category growth.

**Margin beat driven by lower ad spends and better mix**: Gross margins were up 300bps, driven by better pricing as well as improved SKU and product mix. EBITDA margins improved 830bps to 33% (up 280bps qoq) on favorable comparables and lower A&P spends, which declined to 11.6% of sales from 14.5% of sales in Q4FY20. Full-year ad spends normalized at 12.9%, similar to previous years (FY20 saw a high of 13.8%). With an increase in input inflation, we expect margins to moderate slightly, and forecast flat margins for FY22-24E.

**Steady growth with reasonable valuations; maintain Buy:** Market share is yet to see any meaningful recovery but overall performance has been stable. Management actions to improve growth appear positive. Valuation at 35x FY23E EPS appears reasonable and can rerate with market share gains. Maintain Buy with a TP of Rs1,820, based on 40x Jun-23 EPS.

Please see our sector model portfolio (Emkay Alpha Portfolio): Consumer Goods & Retail (page 8) Financial Snapshot (Standalone)

(Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	45,251	48,412	52,637	57,487	62,808
EBITDA	12,017	15,096	15,904	17,815	19,576
EBITDA Margin (%)	26.6	31.2	30.2	31.0	31.2
APAT	7,855	10,039	10,615	12,030	13,312
EPS (Rs)	28.9	36.9	39.0	44.2	48.9
EPS (% chg)	10.3	27.8	5.7	13.3	10.7
ROE (%)	51.7	62.9	65.9	71.5	74.3
P/E (x)	55.3	43.3	40.9	36.1	32.6
EV/EBITDA (x)	35.8	28.2	26.7	23.8	21.5
P/BV (x)	27.2	27.2	26.7	25.0	23.5

Source: Company, Emkay Research



Your success is our success

СМР	Target Price
<b>Rs 1,597</b> as of (May 17, 2021)	Rs 1,820 (▲) 12 months
Rating	Upside
BUY (∎)	14.0 %

#### Change in Estimates

. <b>J</b>		
EPS Chg FY22E/FY23E	(%)	(0.7)/0.3
Target Price change (%)	)	1.1
Target Period (Months)		12
Previous Reco		BUY
Emkay vs Consensus		
EPS Estim	ates	
	FY22E	FY23E
Emkay	39.0	44.2
Consensus	38.0	42.1
Mean Consensus TP (12	2M)	Rs 1,666
Stock Details		
Bloomberg Code		CLGT IN
Face Value (Rs)		1
Shares outstanding (mn)	)	272
52 Week H/L	1,6	76 / 1,257
M Cap (Rs bn/USD bn)	2	34 / 5.93
Daily Avg Volume (nos.)		5,34,501
Daily Avg Turnover (USS	\$ mn)	11.4
Shareholding Pattern I	Mar '21	
Promoters		51.0%
Fils		16.9%
		10 00/-
DIIs Public and Others		10.0%
Public and Others		10.0% 22.1%
Public and Others	л 6N	22.1%
Public and Others       Price Performance       (%)     1M       Absolute     2	- 4	22.1%
Public and Others       Price Performance       (%)     1M       Absolute     2	-	22.1%
Public and OthersPrice Performance(%)1MAbsolute2	- 4	22.1%
Public and Others Price Performance (%) 1M 3M Absolute 2 Rel. to Nifty - 2 Relative price chart 1650 Rs	- 4	22.1%
Public and Others Price Performance (%) 1M 3M Absolute 2 Rel. to Nifty - 2 Relative price chart 1650 Rs	- 4	22.1% <b>1 12M</b> + 18 ) (28)
Public and Others Price Performance (%) 1M 3M Absolute 2 Rel. to Nifty - 2 Relative price chart	- 4	22.1% <b>1 12M</b> <b>4 18</b> <b>0 (28)</b> % 0
Public and Others Price Performance (%) 1M 3M Absolute 2 Rel. to Nifty - 2 Relative price chart 1650 Rs	- 4	22.1% <b>1 12M</b> + 18 (28) % 0 -8
Public and Others Price Performance (%) 1M 3M Absolute 2 Rel. to Nifty - 2 Relative price chart 1650 1560 1470	- 4	22.1% <b>1 12M</b> <b>4 18</b> <b>0 (28)</b> <b>%</b> <b>16</b> <b>16</b>
Public and Others Price Performance (%) 1M 3M Absolute 2 Rel. to Nifty - 2 Relative price chart 1650 1470 1380	- 4	22.1% <b>1 12M</b> + 18 (28) 
Public and Others  Price Performance  (%) 1M 3M  Absolute 2  Rel. to Nifty - 2  Relative price chart  1650 1470 1380 1290 May-20 Jul-20 Sep-20Nov-20	- 4 2 (10)	22.1% 1 12M 1 18 (28) (28) (28) (28) 
Public and Others  Price Performance  (%) 1M 3M  Absolute 2  Rel. to Nifty - 2  Relative price chart  1650 1470 1380 1290 May-20 Jul-20 Sep-20Nov-20 Colgate-Palmolive (LHS)	- 4 2 (10)	22.1% $12M$ $18$ $(28)$ $(28)$ $(28)$ $-6$ $-16$ $-24$ $-32$ $-32$ $-40$
Public and Others  Price Performance  (%) 1M 3M  Absolute 2  Rel. to Nifty - 2  Relative price chart  1650 1470 1380 1290 May-20 Jul-20 Sep-20Nov-20	- 4 2 (10) 	22.1% 1 12M 1 18 (28) (28) (28) (28) -8 -16 -24 -24 -32 -40 -21May-21 H to Nifty (RHS) Global. The
Public and Others Price Performance (%) 1M 3M Absolute 2 Rel. to Nifty - 2 Relative price chart 1650 1470 1380 1290 1200 May-20 Jul-20 Sep-20Nov-20 Colgate-Paimolive (LHS) Source: Bloomberg This report is solely produced following person(s) are respon	- 4 2 (10) 	22.1% 1 12M 1 18 (28) (28) (28) (28) -8 -16 -24 -24 -32 -40 -21May-21 H to Nifty (RHS) Global. The
Public and Others Price Performance (%) 1M 3M Absolute 2 Rel. to Nifty - 2 Relative price chart 1650 1470 1380 1290 1200 Cogate-Palmolive (LHS) Source: Bloomberg This report is solely produced following person(s) are respon production of the recommended	- 4 2 (10)	22.1% 1 12M 1 18 (28) (28) (28) (28) -8 -16 -24 -24 -32 -40 -21May-21 H to Nifty (RHS) Global. The
Public and Others Price Performance (%) 1M 3M Absolute 2 Rel. to Nifty - 2 Relative price chart 1650 1470 1380 1290 Colgate-Palmolive (LHS) Source: Bloomberg This report is solely produced following person(s) are respon production of the recommende Ashit Desai	- 4 2 (10)	22.1% 1 12M 1 18 (28) (28) (28) (28) -8 -16 -24 -24 -32 -40 -21May-21 H to Nifty (RHS) Global. The
Public and Others Price Performance (%) 1M 3M Absolute 2 Rel. to Nifty - 2 Relative price chart 1650 1470 1380 1290 Colgate-Palmolive (LHS) Source: Bloomberg This report is solely produced following person(s) are respon production of the recommende Ashit Desai ashit.desai@emkaygloba	- 4 2 (10)	22.1% 1 12M 1 18 (28) (28) (28) (28) -8 -16 -24 -24 -32 -40 -21May-21 H to Nifty (RHS) Global. The

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

50%

40%

30%

20%

10%

0%

-10%

-20%

-30%

16%

20

3QFY2

A&P Growth % - RHS

12%

4QFY21


13%

2QFY21

11%


10FY26

## Exhibit 1: Sales growth of 20% driven by double-digit growth across categories on low comparables




Source: Company, Emkay Research

#### Exhibit 3: Price increases and lower ad spends drive margin gains



Source: Company, Emkay Research

## Exhibit 5: Other overheads (as % of sales) decline, indicating cost savings



Source: Company, Emkay Research

#### Exhibit 7: Actual vs. Estimates (Q4FY21)


Source: Company, Emkay Research

**QFY20** 

#### Exhibit 6: One-year forward P/E band chart

2QFY20

A&P (% of net sales) - LHS




Source: Company, Emkay Research

Do mo	Actual	Emkay	Consensus	% vai	riation	Commont
Rs mn	Actual	estimate	estimate	Emkay	Consensus	Comment
Revenues	12,832	12,669	12,456	1.3%	3.0%	Recovery in toothbrush and urban business aids revenue growth
EBITDA	4,218	3,798	3,579	11.0%	17.8%	
EBITDA Margin (%)	32.9%	30.0%	28.7%	289	413	Lower ad spends drive operating margin gains
APAT	2,832	2,529	2,405	12.0%	17.8%	

Source: Company, Emkay Research

#### Exhibit 2: Indicative domestic volume growth at 16%; improving qoq



Source: Company, Emkay Research

14%

14%

4QFY19

20%

15%

10%

5%

0%

#### Exhibit 4: Lower A&P spends on a high base of last year

13%

**3QFY20** 

14%

15%

0

4QFY20

#### Exhibit 8: Quarterly Performance (Standalone)

Y/E, Mar (Rs mn)	4QFY20	1QFY21	2QFY21	3QFY21	4QFY21	YoY (%)	QoQ (%)	FY20	FY21	YoY (%)
Revenue	10,713	10,406	12,855	12,319	12,832	19.8	4.2	45,251	48,412	7.0
Expenditure	8,084	7,326	8,762	8,613	8,614	6.6	0.0	33,234	33,316	0.2
Consumption of RM	3,786	3,524	4,096	3,725	4,149	9.6	11.4	15,729	15,494	-1.5
as % of sales	35.3%	33.9%	31.9%	30.2%	32.3%			34.8%	32.0%	
Employee Cost	899	907	966	869	915	1.8	5.3	3,323	3,656	10.0
as % of sales	8.4%	8.7%	7.5%	7.1%	7.1%			7.3%	7.6%	
Advertising & SP	1,555	1,139	1,644	1,983	1,489	-4.3	-24.9	6,260	6,255	-0.1
as % of sales	14.5%	10.9%	12.8%	16.1%	11.6%			13.8%	12.9%	
Other expenditure	1,844	1,757	2,056	2,036	2,062	11.8	1.3	7,922	7,911	-0.1
as % of sales	17.2%	16.9%	16.0%	16.5%	16.1%			17.5%	16.3%	
EBITDA	2,629	3,080	4,093	3,706	4,218	60.4	13.8	12,017	15,096	25.6
Depreciation	462	454	461	456	455	-1.6	-0.2	1,979	1,825	-7.8
EBIT	2,167	2,626	3,632	3,251	3,763	73.7	15.8	10,037	13,271	32.2
Other Income	196	63	76	99	66	-66.3	-33.0	492	304	-38.4
Interest cost	20	20	18	19	16	-21.2	-17.5	96	73	
Exceptional items	0	0	0	0	0			0	0	
PBT	2,344	2,669	3,689	3,330	3,814	62.7	14.5	10,434	13,502	29.4
Total Tax	302	687	947	847	667	120.8	-21.2	2,269	3,148	38.8
Reported PAT	2,042	1,982	2,742	2,484	3,147	54.1	26.7	8,165	10,354	26.8
Extra ordinary items	-310	0	0	0	-315			-310	-315	
Adjusted PAT	1,732	1,982	2,742	2,484	2,832	63.5	14.0	7,855	10,039	27.8
Adjusted EPS	6.4	7.3	10.1	9.1	10.4	63.5	14.0	29	37	27.8

Margins (%)	4QFY20	1QFY21	2QFY21	3QFY21	4QFY21	(bps)	(bps)	FY20	FY21	(bps)
Gross Margin	64.7	66.1	68.1	69.8	67.7	300	-210	65.2	68.0	280
EBIDTA	24.5	29.6	31.8	30.1	32.9	830	280	26.6	31.2	460
EBIT	20.2	25.2	28.3	26.4	29.3	910	290	22.2	27.4	520
EBT	21.9	25.6	28.7	27.0	29.7	780	270	23.1	27.9	480
PAT	16.2	19.0	21.3	20.2	22.1	590	190	17.4	20.7	340
Effective Tax rate	12.9	25.7	25.7	25.4	17.5	460	-790	21.7	23.3	160

Source: Company, Emkay Research

#### Exhibit 9: Revision in earnings estimates

		FY22E			FY23E		FY24E
Y/E, Mar (Rs mn)	Earlier	Revised	% Change	Earlier	Revised	% Change	Introduced
Revenues	52,572	52,315	-0.5	57,846	57,148	-1.2	62,452
EBITDA	15,962	15,904	-0.4	17,731	17,815	0.5	19,576
EBITDA Margin (%)	30.4	30.4	0 bps	30.7	31.2	50 bps	31.3
APAT	10,695	10,615	-0.7	11,993	12,030	0.3	13,312
EPS	39.3	39.0	-0.7	44.1	44.2	0.3	48.9

Source: Company, Emkay Research

Exhibit 10: Revenue growth assumptions

	FY20	FY21	FY22E	FY23E	FY24E
Toothpaste Volume Growth	1%	4%	6%	6%	6%
Toothpaste Realization growth	1%	4%	3%	3%	3%
Revenue (Rs mn)	45,251	48,412	52,637	57,487	62,808
Revenue Growth	1%	7%	9%	9%	9%

Source: Company, Emkay Research

#### Exhibit 11: Relative valuation

	Price	Мсар	Deee	Target	E	EPS (Rs)			P/E (x)		EV / EBITDA (x)		
	(Rs)	(Rs bn)	Reco	Price (Rs)	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
Asian Paints	2,783	2,669	Hold	2,530	32.7	37.9	48.1	85.0	73.4	57.9	54.9	48.0	38.6
Berger Paints	768	746	Sell	560	7.5	10.4	12.1	102.7	73.5	63.2	61.0	45.8	39.7
Britannia	3,507	845	Buy	4,250	77.1	76.3	87.2	45.5	46.0	40.2	33.9	34.0	30.2
Colgate	1,597	434	Buy	1,820	38.1	39.0	44.2	41.9	40.9	36.1	28.2	26.7	23.8
Dabur	534	943	Hold	530	9.6	10.8	12.6	55.7	49.5	42.3	45.9	39.3	33.5
Emami	508	226	Buy	580	14.5	15.5	17.4	35.2	32.7	29.1	24.9	22.5	19.6
GCPL	841	860	Hold	780	16.0	18.3	21.3	52.7	45.9	39.5	35.4	32.5	28.3
HUL	2,376	5,583	Hold	2,350	34.8	40.8	47.4	68.2	58.2	50.1	46.4	38.7	33.5
ITC	213	2,617	Buy	265	10.5	12.9	14.3	20.3	16.5	14.9	15.2	12.2	10.9
Marico	474	612	Hold	430	9.2	10.6	11.8	51.6	44.6	40.1	37.6	32.1	28.9
Nestle	17,038	1,643	Hold	16,800	217.5	266.9	307.4	78.3	63.8	55.4	52.6	44.5	38.9
Pidilite	1,891	961	Sell	1,360	22.3	24.4	32.0	84.7	77.5	59.1	57.3	53.4	41.3
Radico Khaitan	544	73	Buy	640	18.9	23.0	26.7	28.7	23.7	20.4	17.9	15.0	12.9
United Breweries	1,230	325	Buy	1,450	4.5	15.7	29.5	270.8	78.1	41.7	84.5	38.7	24.1
United Spirits	566	412	Buy	660	6.1	13.4	16.5	93.3	42.3	34.4	44.7	26.0	22.0

Source: Company, Emkay Research

#### Key Financials (Standalone)

#### Income Statement

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	45,251	48,412	52,637	57,487	62,808
Expenditure	33,234	33,316	36,734	39,672	43,231
EBITDA	12,017	15,096	15,904	17,815	19,576
Depreciation	1,979	1,825	1,920	1,966	2,044
EBIT	10,037	13,271	13,984	15,848	17,532
Other Income	492	304	364	401	441
Interest expenses	96	73	80	80	80
РВТ	10,434	13,502	14,268	16,169	17,893
Тах	2,269	3,148	3,653	4,139	4,581
Extraordinary Items	310	315	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	8,165	10,354	10,615	12,030	13,312
Adjusted PAT	7,855	10,039	10,615	12,030	13,312

#### Balance Sheet

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Equity share capital	272	272	272	272	272
Reserves & surplus	15,670	15,688	15,967	17,117	18,189
Net worth	15,942	15,959	16,239	17,389	18,461
Minority Interest	0	0	0	0	0
Loan Funds	0	0	0	0	0
Net deferred tax liability	(1,689)	(1,689)	(1,689)	(1,689)	(1,689)
Total Liabilities	14,253	14,271	14,550	15,700	16,772
Net block	11,229	10,404	10,184	9,917	9,573
Investment	186	186	186	186	186
Current Assets	10,477	14,876	15,887	18,382	21,045
Cash & bank balance	4,213	8,364	9,060	11,090	13,218
Other Current Assets	815	833	867	913	967
<b>Current liabilities &amp; Provision</b>	9,539	11,644	12,155	13,234	14,480
Net current assets	938	3,232	3,732	5,148	6,564
Misc. exp	0	0	0	0	0
Total Assets	14,253	14,271	14,550	15,700	16,772

#### **Cash Flow** FY22E FY23E Y/E Mar (Rs mn) FY20 FY21 FY24E 17,452 PBT (Ex-Other income) (NI+Dep) 9,941 13,199 13,904 15,768 Other Non-Cash items 0 0 0 0 0 Chg in working cap (1,370) 1,856 197 613 712 **Operating Cashflow** 8,871 14,108 12,813 14,689 16,148 Capital expenditure (1, 213)452 (1,700)(1,700)(1,700)**Free Cash Flow** 12,989 14,448 7,658 14,560 11,113 Investments 125 0 0 0 0 Other Investing Cash Flow (492) (304) (364) (401) (441) **Investing Cashflow** (1,088) 452 (1,700) (1,700) (1,700) Equity Capital Raised 0 0 0 0 0 Loans Taken / (Repaid) (777) 0 0 0 0 (12,240) Dividend paid (incl tax) (10,336) (10,336) (10,880) (6,558) Other Financing Cash Flow (133) 0 0 0 0 **Financing Cashflow** (10,960) (7,564) (10,409) (10,416) (12, 320)Net chg in cash 219 4,151 697 2,029 2,128 Opening cash position 3,994 4,213 8,364 9,060 11,090 **Closing cash position** 4,213 8,364 9,060 11,090 13,218

Source: Company, Emkay Research

Profitability (%)	FY20	FY21	FY22E	FY23E	FY24E
EBITDA Margin	26.6	31.2	30.2	31.0	31.2
EBIT Margin	22.2	27.4	26.6	27.6	27.9
Effective Tax Rate	21.7	23.3	25.6	25.6	25.6
Net Margin	18.0	21.4	20.2	20.9	21.2
ROCE	73.1	95.2	99.6	107.4	110.7
ROE	51.7	62.9	65.9	71.5	74.3
RoIC	123.8	200.7	276.2	358.9	508.5
Per Share Data (Rs)	FY20	FY21	FY22E	FY23E	FY24E
EPS	28.9	36.9	39.0	44.2	48.9
CEPS	36.2	43.6	46.1	51.5	56.5
BVPS	58.6	58.7	59.7	63.9	67.9
DPS	20.0	38.0	38.0	40.0	45.0
Valuations (x)	FY20	FY21	FY22E	FY23E	FY24E
PER	55.3	43.3	40.9	36.1	32.6
P/CEPS	43.7	36.2	34.3	30.7	28.0
P/BV	27.2	27.2	26.7	25.0	23.5
EV / Sales	9.6	8.9	8.1	7.4	6.7
EV / EBITDA	35.8	28.2	26.7	23.8	21.5
Dividend Yield (%)	1.3	2.4	2.4	2.5	2.8
Occurican Defici (a)	5)/00	51/04	EV/00E	EV00E	51/045
Gearing Ratio (x)	FY20	FY21	FY22E	FY23E	FY24E
Net Debt/ Equity	(0.3)	(0.5)	(0.6)	(0.6)	(0.7
Net Debt/EBIDTA	(0.4)	(0.6)	(0.6)	(0.6)	(0.7
Working Cap Cycle (days)	(26.4)	(38.7)	(36.9)	(37.7)	(38.7
Growth (%)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	1.4	7.0	8.7	9.2	9.3
EBITDA	(2.8)	25.6	5.3	12.0	9.9
EBIT	(6.8)	32.2	5.4	13.3	10.0
PAT	5.3	26.8	2.5	13.3	10.
Quarterly (Rs mn)	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY2
Revenue	10,713	10,406	12,855	12,319	12,832
EBITDA	2,629	3,080	4,093	3,706	4,218
EBITDA Margin (%)	24.5	29.6	31.8	30.1	32.9
PAT	2,042	1,982	2,742	2,484	3,14
EPS (Rs)	7.5	7.3	10.1	9.1	11.0
Source: Company, Emkay Research					
Shareholding Pattern (%)	Mar-20	Jun-20	Sep-20	Dec-20	Mar-2
Promoters	51.0	51.0	51.0	51.0	51.0
Flls	16.2	15.3	15.7	16.6	16.9
FIIs DIIs	16.2 10.0	15.3 11.2	15.7 10.8	16.6 10.1	16.9 10.0


Source: Capitaline

#### RECOMMENDATION HISTORY TABLE

Date	Closing Price	ТР	Period (months)	Rating	Analyst
29-Jan-21	1,582	1,800	12m	Buy	Ashit Desai
20-Dec-20	1,579	1,700	12m	Buy	Ashit Desai
21-Oct-20	1,392	1,600	12m	Buy	Ashit Desai
29-Jul-20	1,412	1,590	12m	Buy	Ashit Desai
22-May-20	1,266	1,500	12m	Buy	Ashit Desai
14-Apr-20	1,309	1,450	12m	Buy	Ashit Desai
31-Jan-20	1,281	1,620	12m	Buy	Ashit Desai
25-Dec-19	1,422	1,720	12m	Buy	Ashit Desai
24-Oct-19	1,496	1,720	12m	Buy	Ashit Desai
20-Sep-19	1,337	1,610	12m	Buy	Ashit Desai
14-Sep-19	1,200	1,370	12m	Hold	Ashit Desai
18-Jul-19	1,152	1,240	12m	Hold	Ashit Desai
27-May-19	1,121	1,240	12m	Hold	Ashit Desai
09-Apr-19	1,170	1,240	12m	Hold	Ashit Desai
24-Jan-19	1,249	1,240	12m	Hold	Ashit Desai
30-Oct-18	1,032	1,200	12m	Hold	Ashit Desai
27-Jul-18	1,034	1,200	12m	Hold	Ashit Desai
21-May-18	1,124	1,230	12m	Hold	Ashit Desai

**RECOMMENDATION HISTORY CHART** 





Source: Company, Emkay Research

Embray Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.



#### Analyst: Ashit Desai

**Contact Details** 

ashit.desai@emkayglobal.com +91 22 6612 1340

### Sector

Consumer Goods & Retail

#### Analyst bio

Ashit Desai holds a PGDM and FRM (US GARP) with 12 years of research experience on the sell side. His team currently covers 24 stocks in the Indian Consumer and Retail space.

EAP sector portfolio					
Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Consumer Goods & Retail	10.89	10.89	0%	0	100.00
Asian Paints	1.50	0.57	-62%	-93	5.24
Berger Paints	0.22	0.00	-100%	-22	0.00
Britannia Industries	0.50	0.54	9%	5	4.97
Colgate-Palmolive	0.25	0.30	20%	5	2.76
Dabur India	0.36	0.34	-6%	-2	3.12
Emami	0.13	0.16	24%	3	1.46
Godrej Consumer Products	0.39	0.34	-11%	-4	3.15
Hindustan Unilever	2.54	2.07	-19%	-47	19.00
ITC	2.22	2.29	3%	6	21.00
Marico	0.29	0.30	2%	1	2.75
Nestle India	0.74	0.65	-11%	-8	6.00
Pidilite Industries	0.35	0.00	-100%	-35	0.00
Radico Khaitan	0.00	0.35	NA	35	3.20
United Breweries	0.10	0.55	452%	45	5.05
United Spirits	0.00	0.35	NA	35	3.20
Varun Beverages	0.11	0.16	44%	5	1.47
ABFRL	0.07	0.16	145%	10	1.50
Jubilant FoodWorks	0.21	0.25	22%	5	2.34
Page Industries	0.19	0.23	22%	4	2.14
Shoppers Stop	0.00	0.00	NA	0	0.00
Titan Company	0.73	1.01	38%	28	9.25
Westlife Development	0.00	0.26	NA	26	2.40
Cash	0.00	0.00	NA	0	0.00

Emkay Alpha Portfolio – Consumer Goods & Retail

Source: Emkay Research

\* Not under coverage: Equal Weight

High Conviction/Strong Over Weight High Conviction/Strong Under Weight

#### Sector portfolio NAV


	Base					Latest
-	1-Apr-19	15-May-20	13-Nov-20	12-Feb-21	13-Apr-21	14-May-21
EAP - Consumer Goods & Retail	100.0	92.8	108.5	119.8	121.2	124.9
BSE200 Neutral Weighted Portfolio (ETF)	100.0	87.8	104.4	114.8	117.5	118.6

Source: Emkay Research

#### Price Performance (%)

	1m	3m	6m	12m
EAP - Consumer Goods & Retail	3.1%	4.3%	15.1%	34.7%
BSE200 Neutral Weighted Portfolio (ETF)	0.9%	3.3%	13.6%	35.0%
Source: Emkay Research				

NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

#### **Emkay Rating Distribution**

Completed Date: 18 May 2021 14:13:23 (SGT) Dissemination Date: 18 May 2021 14:14:23 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of May 17, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report
- Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of May 17, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the May 17, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the May 17, 2021

RESTRICTIONS ON D	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 <sup>th</sup> Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

#### Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com